Elsayed Hany Hasan, Mostafa Ahmed, Fathy Essam, Diab Haytham S, Nofal Ibrahim Mostafa, AbdelHamid Osama Abbas, El-Bawab Hatem Yazeed, ElNori Ahmed A
Thoracic Surgery Department, Ain Shams University Hospital, Cairo, Egypt.
Pulmonology Department, Ain Shams University Hospital, Cairo, Egypt.
J Vis Surg. 2018 May 29;4:114. doi: 10.21037/jovs.2018.05.18. eCollection 2018.
Empyema is a well-known disease that significantly increases the morbidity and mortality associated with pneumonia. There are a number of treatment modalities available but recently video assisted thoracoscopic surgery (VATS) has been suggested as a reliable tool in management of empyema; particularly in early stages. The aim of this study is to assess the safety and effectiveness of using initial VATS for all surgically fit patients with early stages of empyema.
Sixty-six patients with early stage empyema were prospectively studied between December 2013 and March 2016. Patients were divided into two groups: group A (28 patients) were managed conservatively without surgery for stage I (exudative) phase empyema by the chest physicians; and group B (38 patients) were managed by the thoracic surgeons by VATS for stage I (exudative) and stage II (fibrino-purulent) empyema. Comparison was made between both groups.
There was no statistically significant difference between the groups from the point of view of age, sex or pre-intervention comorbidities (P>0.05). Average hospital stay in group A was 22 days (7-131 days), it was 4.1 days (2-14 days) in group B (P=0.004; 95% CI: 10.3-25.5) with a resultant lower cost. Three patients (10.7%) in group A suffered from major morbidity during treatment while none in group B suffered a major postoperative morbidity (P=0.039). There were 2 mortalities (7.1%) in group A and no deaths in group B (P=0.094). During a mean follow up period of 8 months [6-14] in group A 14.3% of the patients underwent open decortication, whereas in group B, 5.3% of the patients underwent the same procedure (P=0.047).
Thoracoscopic management of early stages of empyema should be the golden standard of management in surgically fit patients; particularly in the fibro-exudative phase of empyema. It is an effective and safe technique that reduces hospital stay, cost, complications and avoids the need for a decortication via a thoracotomy in most cases.
脓胸是一种众所周知的疾病,它显著增加了与肺炎相关的发病率和死亡率。目前有多种治疗方式,但最近电视辅助胸腔镜手术(VATS)被认为是治疗脓胸的可靠工具,尤其是在早期阶段。本研究的目的是评估对所有适合手术的早期脓胸患者采用初始VATS治疗的安全性和有效性。
2013年12月至2016年3月期间,对66例早期脓胸患者进行了前瞻性研究。患者分为两组:A组(28例)由胸科医生对I期(渗出性)脓胸进行保守治疗,不进行手术;B组(38例)由胸外科医生对I期(渗出性)和II期(纤维脓性)脓胸进行VATS治疗。对两组进行比较。
从年龄、性别或干预前合并症的角度来看,两组之间无统计学显著差异(P>0.05)。A组的平均住院时间为22天(7 - 131天),B组为4.1天(2 - 14天)(P = 0.004;95%置信区间:10.3 - 25.5),成本更低。A组有3例患者(10.7%)在治疗期间发生严重并发症,而B组无患者发生重大术后并发症(P = 0.039)。A组有2例死亡(7.1%),B组无死亡(P = 0.094)。在A组平均8个月[6 - 14]的随访期内,14.3%的患者接受了开胸剥脱术,而在B组,5.3%的患者接受了相同手术(P = 0.047)。
对于适合手术的患者,尤其是在脓胸的纤维渗出期,胸腔镜治疗早期脓胸应成为治疗的金标准。这是一种有效且安全的技术,可缩短住院时间、降低成本、减少并发症,并且在大多数情况下避免了开胸剥脱术的需要。